DCT

3:26-cv-07370

Rayner Surgical Inc v. Mankind Pharma Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-07370, D.N.J., 06/18/2026
  • Venue Allegations: Venue is alleged to be proper as to Mankind Pharma Ltd. because it is a foreign corporation that may be sued in any judicial district. Venue is alleged to be proper as to Lifestar Pharma LLC because it has a regular and established place of business in New Jersey.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' OMIDRIA® product constitutes an act of infringement of three U.S. patents directed to stable, preservative-free ophthalmic solutions.
  • Technical Context: The technology concerns injectable pharmaceutical formulations used during cataract surgery to maintain pupil dilation (mydriasis) and reduce postoperative pain, addressing the need for stable solutions that do not contain potentially toxic preservatives or antioxidants.
  • Key Procedural History: This is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2) in response to Defendants' submission of ANDA No. 221449 containing a Paragraph IV certification. The patents-in-suit are listed in the FDA's Orange Book for the OMIDRIA® drug product. The complaint notes prior litigation involving the same patents against other generic drug manufacturers.

Case Timeline

Date Event
2012-10-24 Earliest Priority Date for '856, '406, and '246 Patents
2014-05-01 FDA Approval of OMIDRIA® New Drug Application (NDA)
2015-06-30 '856 Patent Issued
2016-11-08 '406 Patent Issued
2018-01-02 '246 Patent Issued
2026-05-04 Defendants' Paragraph IV Notice Letter Sent
2026-06-18 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,066,856

  • Patent Identification: U.S. Patent No. 9,066,856, "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection," issued June 30, 2015 Compl. ¶30
  • The Invention Explained:
    • Problem Addressed: During intraocular surgery, maintaining pupil dilation (mydriasis) is critical, but the iris tends to constrict (miosis), increasing procedural risk ʼ856 Patent, col. 1:49-61 Additionally, existing injectable solutions used to counteract this, such as those containing epinephrine, often include preservatives (e.g., benzalkonium chloride) or antioxidants (e.g., sodium metabisulfite) that can be toxic to sensitive intraocular tissues ʼ856 Patent, col. 2:1-14
    • The Patented Solution: The patent describes a liquid pharmaceutical formulation that combines a mydriatic agent (phenylephrine) and an anti-inflammatory agent (ketorolac) in a buffered aqueous solution that is free of both preservatives and antioxidants ʼ856 Patent, abstract This formulation is designed to be injected into a standard intraocular irrigation solution used during surgery, providing a method to maintain mydriasis and reduce pain without introducing potentially toxic additives ʼ856 Patent, col. 3:46-54
    • Technical Importance: The invention provided a method for delivering a combination of therapeutic agents to maintain pupil dilation and control pain during ocular surgery, while addressing the long-standing problem of excipient-related toxicity by creating a stable formulation without preservatives or antioxidants ʼ856 Patent, col. 2:15-24
  • Key Claims at a Glance:
    • The complaint recites independent claim 1 Compl. ¶42
    • The essential elements of independent claim 1 are:
      • A sterile liquid pharmaceutical formulation
      • consisting essentially of phenylephrine, ketorolac and a buffer system
      • in an aqueous carrier,
      • wherein the formulation is stable for at least six months when stored at a temperature of from 5+/-3° C. to 25 +/-2° C.
    • The complaint incorporates by reference all preceding paragraphs, which mention infringement of "one or more claims," suggesting the right to assert other claims may be reserved Compl. ¶38

U.S. Patent No. 9,486,406

  • Patent Identification: U.S. Patent No. 9,486,406, "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection," issued November 8, 2016 Compl. ¶31
  • The Invention Explained:
    • Problem Addressed: As with the parent '856 Patent, this patent addresses the need for a stable combination of a mydriatic (phenylephrine) and an NSAID (ketorolac) for use in ophthalmic surgery, specifically noting the toxicity concerns associated with preservatives and antioxidants found in prior art formulations '406 Patent, col. 1:53-col. 2:14
    • The Patented Solution: The patent describes a liquid pharmaceutical formulation containing phenylephrine and ketorolac in a buffered aqueous carrier that achieves stability without the inclusion of preservatives and antioxidants '406 Patent, abstract '406 Patent, col. 3:52-61 This solution is intended for dilution into an irrigation fluid for use during surgery.
    • Technical Importance: The invention offers a solution for simultaneously maintaining pupil dilation and reducing pain/inflammation during eye surgery, while explicitly avoiding the use of potentially toxic preservatives and antioxidants, thereby enhancing patient safety '406 Patent, col. 2:15-24
  • Key Claims at a Glance:
    • The complaint recites independent claim 2 Compl. ¶62
    • The essential elements of independent claim 2 are:
      • A liquid pharmaceutical formulation
      • comprising phenylephrine, ketorolac and a buffer system
      • in an aqueous carrier,
      • wherein the formulation is stable without the inclusion of preservatives and antioxidants for at least six months when stored at a temperature of from 5+/-3°C. to 25+/-2° C.
    • The complaint incorporates by reference all preceding paragraphs, which mention infringement of "one or more claims," suggesting the right to assert other claims may be reserved Compl. ¶58

U.S. Patent No. 9,855,246 (Multi-Patent Capsule)

  • Patent Identification: U.S. Patent No. 9,855,246, "Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection," issued January 2, 2018 Compl. ¶32
  • Technology Synopsis: This patent, part of the same family, is directed to a liquid intraocular ophthalmic pharmaceutical solution dosage form. It specifically claims the combination of phenylephrine and ketorolac in a pH-adjusted, buffered solution that is free of preservatives, antioxidants, and solubilizing agents, and further specifies that this solution is contained in a single-use container with a nitrogen gas overlay to enhance stability '246 Patent, abstract The patent also recites specific concentration ranges for the active ingredients '246 Patent, claim 1
  • Asserted Claims: The complaint recites independent claim 1 Compl. ¶82
  • Accused Features: The complaint alleges that Defendants' ANDA Product is a liquid intraocular ophthalmic solution dosage form that meets all the limitations of claim 1, including the specified components, concentrations, stability, and packaging within a single-use container with a nitrogen gas overlay Compl. ¶83

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Defendants' proposed generic version of OMIDRIA® (phenylephrine and ketorolac injection, 1%/0.3%), which is the subject of ANDA No. 221449 (the "ANDA Product") Compl. ¶1
  • Functionality and Market Context: The ANDA Product is a sterile liquid pharmaceutical formulation intended for dilution into an ocular irrigating solution for use during cataract surgery or intraocular lens replacement Compl. ¶25 Its purposes are to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain Compl. ¶25 The complaint alleges that, to gain FDA approval, the ANDA product must generally contain the same active and inactive ingredients in the same concentrations as the reference listed drug, OMIDRIA® Compl. ¶41 Plaintiffs allege that Defendants intend to commercially manufacture and sell the ANDA Product in the United States, thereby displacing sales of OMIDRIA® Compl. ¶20

IV. Analysis of Infringement Allegations

The infringement allegations are based on Defendants' submission of ANDA No. 221449, which Plaintiffs contend is an act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶40 Compl. ¶60 The complaint asserts that because the ANDA Product seeks approval as a generic version of OMIDRIA®, it will necessarily have the same formulation and stability characteristics recited in the patent claims Compl. ¶41 Compl. ¶61

The OMIDRIA® prescribing information, attached as Exhibit A to the complaint, includes a chart demonstrating the product's efficacy in maintaining pupil size during surgery compared to a placebo. Compl., Ex. A at 31 This chart, "Intraoperative Pupil Diameter (mm) Change-from-Baseline," visually supports the core purpose of the patented technology by showing that pupil diameter in Omidria-treated groups remained relatively stable, whereas it progressively constricted in placebo-treated groups.

'856 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A sterile liquid pharmaceutical formulation The ANDA Product is alleged to be a sterile liquid pharmaceutical formulation. ¶43 col. 3:46-47
consisting essentially of phenylephrine, ketorolac and a buffer system The ANDA Product is alleged to consist essentially of phenylephrine, ketorolac, and a buffer system, based on FDA regulations requiring sameness for generic ophthalmic drugs. ¶41; ¶43 col. 3:47-49
in an aqueous carrier, The ANDA Product is alleged to be formulated in an aqueous carrier. ¶43 col. 3:49-50
wherein the formulation is stable for at least six months when stored at a temperature of from 5+/-3° C. to 25 +/-2° C. The ANDA Product is alleged to meet this stability requirement to be approved as a generic equivalent of OMIDRIA®. ¶43 col. 3:50-54

'406 Patent Infringement Allegations

Claim Element (from Independent Claim 2) Alleged Infringing Functionality Complaint Citation Patent Citation
A liquid pharmaceutical formulation comprising phenylephrine, ketorolac and a buffer system in an aqueous carrier, The ANDA Product is alleged to be a liquid pharmaceutical formulation comprising these components, based on its status as a generic version of OMIDRIA®. ¶63 col. 11:2-4
wherein the formulation is stable without the inclusion of preservatives and antioxidants for at least six months when stored at a temperature of from 5+/-3°C. to 25+/-2° C. The ANDA Product is alleged to be stable for the required period and, like OMIDRIA®, is free of preservatives and antioxidants. ¶26; ¶63 col. 11:4-8
  • Identified Points of Contention:
    • Scope Questions: The term "consisting essentially of" in the '856 Patent will be a primary focus. The infringement analysis will question whether Defendants' ANDA Product contains any unlisted ingredients and, if so, whether those ingredients materially affect the "basic and novel properties" of the claimed invention, which the patentee may argue is stability in the absence of preservatives and antioxidants ('856 Patent, col. 9:44-52).
    • Technical Questions: A central technical question is whether the ANDA Product actually meets the claimed stability profile ("stable for at least six months"). The complaint makes this allegation on "information and belief" Compl. ¶43 Compl. ¶63, premised on the requirements for FDA approval. The case will depend on the actual, undisclosed stability data contained within the ANDA.

V. Key Claim Terms for Construction

  • The Term: "consisting essentially of" ('856 Patent, Claim 1)

  • Context and Importance: This transitional phrase defines the scope of the claimed formulation. Its construction is critical because it will determine whether any additional, unlisted excipients in the Defendants' ANDA product would allow it to avoid infringement. Practitioners may focus on this term because it is a well-established term of art with a specific legal meaning that is narrower than "comprising" but broader than "consisting of."

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent does not provide an explicit definition for the term, which may lead parties to argue for the default interpretation allowing for unlisted ingredients that do not materially affect the invention's basic and novel characteristics.
    • Evidence for a Narrower Interpretation: Plaintiffs may argue that the "basic and novel" characteristic is the achievement of stability in a "very pure" formulation specifically lacking preservatives and antioxidants, as highlighted in the specification ('856 Patent, col. 9:48-52). This could support a reading where any additional ingredient that could potentially affect stability or toxicity, even if not a classic preservative, would be considered a material alteration.

  • The Term: "stable" ('856 Patent, Claim 1; '406 Patent, Claim 2)

  • Context and Importance: This term defines a required performance characteristic of the formulation and is central to the infringement analysis. Infringement will depend on whether the ANDA product's stability data meets the specific threshold defined in the patent.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification provides an explicit definition: a formulation is "stable" if it "contains less than 5% total related substances" after a specified storage period ('856 Patent, col. 8:19-22). Defendants may argue that this is the sole definition and meeting this 5% threshold is sufficient.
    • Evidence for a Narrower Interpretation: The specification also states that "[i]n a preferred embodiment of the invention, the stable formulations of the invention have less than 1.0% total related substances after a given storage period" ('856 Patent, col. 8:34-37). Plaintiffs may argue this passage informs the meaning of "stable" as understood by a person of ordinary skill, suggesting a much lower impurity level is what the inventors truly regarded as stable for the purposes of the invention.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Defendants will induce infringement by marketing and distributing the ANDA Product with a product insert and prescribing information that will instruct healthcare professionals and others to use the product in an infringing manner Compl. ¶46 Compl. ¶66 Compl. ¶86
  • Willful Infringement: The complaint alleges that Defendants had actual and constructive notice of the patents-in-suit prior to filing the ANDA, based on the patents' listing in the FDA's Orange Book Compl. ¶29 Compl. ¶47 Compl. ¶67 Compl. ¶87 The filing of a Paragraph IV certification is also presented as evidence of willfulness. Based on this alleged conduct, Plaintiffs assert the case is "exceptional" and seek enhanced damages and attorneys' fees Compl. ¶48 Compl. ¶68 Compl. ¶88

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of claim scope: can the term "consisting essentially of," as used in the '856 Patent, be interpreted to permit additional excipients in the accused generic product without materially altering the formulation's core properties of purity and stability in the absence of preservatives and antioxidants?

  • A key evidentiary question will be one of factual correspondence: does the chemical composition and demonstrated stability profile of Defendants' ANDA product, as confidentially submitted to the FDA, actually meet the specific concentration, pH, and stability limitations recited in the asserted claims? The outcome will likely hinge on a comparison of the ANDA data against the explicit definitions and embodiments in the patents.

  • A foundational question will be one of patent validity: although not detailed in the complaint, Defendants' Paragraph IV notice implies an assertion of invalidity. The case may therefore turn on whether Defendants can prove, by clear and convincing evidence, that the asserted claims are invalid as obvious or anticipated by prior art related to ophthalmic solutions.

Loading Complaint